Wilson analyst report sums it up well indicating the efti+Keytruda should be first choice
"This OS data suggests clinicians many no longer need to weigh up incremental survival benefit with add-on chemo, and associated side effect burden, with the Efti combination able to deliver on OS (matching/bettering chemo) with a superior tolerability profile.
This is compelling and we expect IMM to be a hot topic of discussion at ASCOin a few weeks’ time (June 2-6th), having demonstrated such impressive OS data in the absenceof chemotherapy."
(Benson, Storey, & Williams, 2023)
Wilson analyst report sums it up well indicating the...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.8¢ | $684.8K | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 436502 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 92443 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |